Novel therapeutic approaches for the treatment of castration-resistant prostate cancer
Open Access
- 1 November 2013
- journal article
- review article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 138, 248-256
Abstract
No abstract availableKeywords
Funding Information
- Austrian Research Fund (W0110-B2)
- Autonomous Province of Bolzano-South Tyrol (37/40.3)
This publication has 95 references indexed in Scilit:
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Contemporary Role of Androgen Deprivation Therapy for Prostate CancerEuropean Urology, 2012
- Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancerThe EMBO Journal, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyThe Lancet, 2010
- Final analysis of a phase II trial using sorafenib for metastatic castration‐resistant prostate cancerBJU International, 2009
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate CancerScience, 2009
- Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 TrialEuropean Urology, 2009
- Structural basis for antagonism and resistance of bicalutamide in prostate cancerProceedings of the National Academy of Sciences, 2005